Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II ...

IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing ...

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Michael Hofman presented an in-depth ...

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C ...

Notably, treatment usage trends from a Bladder Cancer Advocacy Network (BCAN) survey presented at GU ASCO 2025 revealed that only 1–5% of patients reported having seen a radiation oncologist and only ...

A year after Mbappe's move to Real Madrid, PSG are European champions for the first time after hammering Inter 5-0 in Munich ...